유럽종 포도의 씨 추출물을 함유하는 골다공증 예방 또는 치료용 약학 조성물
    51.
    发明公开
    유럽종 포도의 씨 추출물을 함유하는 골다공증 예방 또는 치료용 약학 조성물 有权
    用于预防或治疗包含VITIS VINIFERA PIP提取物的OSTEOPOSOSIS的药物组合物

    公开(公告)号:KR1020100067708A

    公开(公告)日:2010-06-22

    申请号:KR1020080126216

    申请日:2008-12-12

    CPC classification number: A61K36/87

    Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to suppress osteoclast differentiation and to prevent and treat osteoporosis. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The Vitis vinifera seed extract has 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanine. A method for manufacturing the Vitis vinifera seed extract comprises: a step of adding mixture solvent of water and acetone to pulverized Vitis vinifera seed and extracting at room temperature; a step of removing acetone and suturing sodium chloride and filtering; a step of extracting the extract with acetate and concentrating; and a step of adding chloroform to the concentrate and filtering.

    Abstract translation: 目的:提供含有葡萄籽提取物的药物组合物,以抑制破骨细胞分化和预防和治疗骨质疏松症。 构成:用于预防或治疗骨质疏松症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物的原花青素值(PCV)为80-130,儿茶素和( - )表儿茶素为30%以下,原花青素为95-105%。 葡萄种子提取物的制造方法包括:将水和丙酮的混合溶剂加入粉状葡萄种子并在室温下提取的步骤; 去除丙酮并缝合氯化钠并过滤的步骤; 用醋酸提取提取物浓缩的步骤; 以及向浓缩物中加入氯仿并过滤的步骤。

    유럽종 포도의 씨 추출물을 함유하는 비만의 예방 또는 치료용 약학 조성물
    53.
    发明公开
    유럽종 포도의 씨 추출물을 함유하는 비만의 예방 또는 치료용 약학 조성물 无效
    用于预防或治疗包含VITIS VINIFERA PIP提取物的药物的药物组合物

    公开(公告)号:KR1020110137588A

    公开(公告)日:2011-12-23

    申请号:KR1020100057601

    申请日:2010-06-17

    Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract and pharmaceutically acceptable carrier is provided to prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract has 80-130 of procyanidolic value(PCV) and contains less than 30% of (+)catechin and (-) epicatechin and 95-105% of proanthocyanidin content. A method for preparing the extract comprises: a step of mixing pulverized Vitis vinifera seed and a mixture solvent of acetone and water and isolating at room temperature; a step of filtering the extract and distilling the filtered liquid to remove acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering.

    Abstract translation: 目的:提供含有葡萄籽提取物和药学上可接受的载体的药物组合物以预防和治疗肥胖症。 构成:用于预防或治疗肥胖症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 提取物具有80-130原花青素值(PCV),并且含有少于30%的(+)儿茶素和( - )表儿茶素和95-105%的原花色素含量。 一种制备提取物的方法包括:将经粉碎的葡萄种子和丙酮和水的混合溶剂混合并在室温下分离的步骤; 过滤提取物并蒸馏过滤的液体以除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤步骤。

    유럽종 포도의 씨 추출물을 함유하는 위장관 궤양의 예방 또는 치료용 약학 조성물
    56.
    发明公开
    유럽종 포도의 씨 추출물을 함유하는 위장관 궤양의 예방 또는 치료용 약학 조성물 有权
    用于预防或治疗包含VITIS VINIFERA PIP提取物的胃肠道溃疡的药物组合物

    公开(公告)号:KR1020110049627A

    公开(公告)日:2011-05-12

    申请号:KR1020100025050

    申请日:2010-03-22

    Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to prevent and treat gastrointestinal ulcer. CONSTITUTION: A pharmaceutical composition for preventing or treating gastrointestinal ulcer contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract of Vitis vinifera seeds contains 80-130 of procyanidolic value(PCV); 30% or less of (+)catechin and (-) epicatechin; and 95-105% of proanthocyanidin. A method for preparing the Vitis vinifera seed extract comprises: a step of extracting Vitis vinifera seed seeds in a mixture solvent of acetone and water and filtering; a step of distilling liquid and removing acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering to obtain precipitate.

    Abstract translation: 目的:提供含有葡萄籽提取物的药物组合物,用于预防和治疗胃肠溃疡。 构成:用于预防或治疗胃肠溃疡的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物含有原花青素含量(PCV)80-130; 30%以下(+)儿茶素和( - )表儿茶素; 和95-105%的原花色素。 一种葡萄种子提取物的制备方法,其特征在于:在丙酮和水的混合溶剂中提取葡萄种子种子并过滤; 蒸馏液并除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤以获得沉淀物的步骤。

    유럽종 포도의 씨 추출물을 함유하는 골관절염 예방 또는 치료용 약학 조성물
    57.
    发明公开
    유럽종 포도의 씨 추출물을 함유하는 골관절염 예방 또는 치료용 약학 조성물 有权
    用于预防或治疗包含VITIS VINIFERA PIP提取物的药物组合物的药物组合物

    公开(公告)号:KR1020100117184A

    公开(公告)日:2010-11-03

    申请号:KR1020090035796

    申请日:2009-04-24

    CPC classification number: A61K36/87

    Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera for preventing or treating osteoarthritis is provided. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoarthritis contains Vitis vinifera extract and pharmaceutically acceptable carrier. Osteoarthritis is caused by aging, obesity or trauma. The Vitis vinifera extract contains 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanidine. A method for producing Vitis vinifera extract comprises: a step of extracting Vitis vinifera and mixture of acetone and water at room temperature and filtering; a step of distilling remaining liquid and removing acetone; a step of saturating sodium chloride and filtering; a step of extracting with ethyl acetate and concentrating; and a step of adding chloroform and precipitating.

    Abstract translation: 目的:提供一种含有葡萄酒的预防或治疗骨关节炎的药物组合物。 构成:用于预防或治疗骨关节炎的药物组合物含有葡萄葡萄提取物和药学上可接受的载体。 骨关节炎是由衰老,肥胖或创伤引起的。 葡萄籽提取物含有原花青素值(PCV)80-130,儿茶素和( - )表儿茶素30%以下,原花青素95-105%。 一种葡萄酒提取物的制备方法,其特征在于:在室温下提取葡萄酒和丙酮与水的混合物,过滤; 蒸馏剩余液体并除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯提取并浓缩的步骤; 并加入氯仿和沉淀的步骤。

    유럽종 포도의 씨 추출물의 제조방법 및 이를 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물
    58.
    发明公开
    유럽종 포도의 씨 추출물의 제조방법 및 이를 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물 有权
    制备VITIS VINIFERA PIP萃取物和药物组合物的方法,用于预防或治疗包含其中的RHEUMATOID ARTHRITIS

    公开(公告)号:KR1020090024647A

    公开(公告)日:2009-03-09

    申请号:KR1020080087109

    申请日:2008-09-04

    CPC classification number: A61K36/87

    Abstract: A method for preparing extracts from seeds of Vitis Vinifera is provided to reduce the quantity of acetone consumed for extraction by using a mixed solvent of water and acetone while securing a high yield. A method for preparing extracts from seeds of Vitis Vinifera comprises the following steps of: extracting an extract from a mixture of pulverized seeds of the Vitis Vinifera and a acetone/water mixed solvent in a mixing ratio of 1 to 1-2 at a room temperature and filtering the extract; removing the acetone by distilling the obtained extract and saturating the extract with sodium chloride; extracting the saturated extract by ethylacetate and concentrating the extract; and adding chloroform to the concentrated extract to obtain precipitate.

    Abstract translation: 提供了一种用于从酿酒酵母的种子制备提取物的方法,以通过使用水和丙酮的混合溶剂来减少用于提取的丙酮消耗量,同时确保高产率。 从酿酒酵母种子提取提取物的方法包括以下步骤:将葡萄酒的粉碎种子和丙酮/水混合溶剂的混合物中的提取物以1至1-2的混合比在室温下萃取 并过滤提取物; 通过蒸馏所得提取物并用氯化钠饱和提取物除去丙酮; 用乙酸乙酯提取饱和提取物,浓缩提取物; 并向浓缩的萃取液中加入氯仿,得到沉淀。

    황반변성 예방 또는 치료용 약학 조성물
    59.
    发明公开
    황반변성 예방 또는 치료용 약학 조성물 审中-实审
    用于预防或治疗谷物变性的药物组合物

    公开(公告)号:KR1020120112162A

    公开(公告)日:2012-10-11

    申请号:KR1020120032161

    申请日:2012-03-29

    CPC classification number: A61K9/0048 A61K31/4178

    Abstract: PURPOSE: A pharmaceutical composition containing secondary amine-substituted benzopyrane derivative is provided to prevent or treat macular degeneration. CONSTITUTION: A pharmaceutical composition for preventing or treating macular degeneration contains a compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The composition is used in the form of eye drops and the active ingredients are delivery to retina. Eye drops for preventing or treating macular degeneration contain the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating macular degeneration contains (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazole-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyrane or pharmaceutically acceptable salt thereof as an active ingredient.

    Abstract translation: 目的:提供含有仲胺取代苯并吡喃衍生物的药物组合物,用于预防或治疗黄斑变性。 构成:用于预防或治疗黄斑变性的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。 组合物以眼药水的形式使用,活性成分被输送到视网膜。 用于预防或治疗黄斑变性的眼药水含有化学式1的化合物或其药学上可接受的盐作为活性成分。 用于预防或治疗黄斑变性的药物组合物含有(2R,3R,4S)-6-氨基-4- [N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基] -3-羟基 -2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃或其药学上可接受的盐作为活性成分。

Patent Agency Ranking